Plant Name: Diospyros peregrina
Taxonomic Information:
Plant ID: NPO12233
Plant Latin Name: Diospyros peregrina
Taxonomy Genus: Diospyros
Taxonomy Family: Ebenaceae
Plant External Links:
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
IndiaTraditional Medicine System:
Indian Folk; Unani; Ayurveda; SiddhaGeographical Distribution:
India
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| CNR1; CNR2; | |
| TSHR; | |
| TRPA1; TRPV1; | |
| PPARD; PPARA; | |
| ALOX15; | |
| TLR2; | |
| FABP3; FABP2; FABP4; LMNA; FABP5; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | CNR1 | Cannabinoid CB1 receptor | P21554 | CHEMBL218 |
| Small molecule receptor (family A GPCR) | CNR2 | Cannabinoid CB2 receptor | P34972 | CHEMBL253 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Transient receptor potential channel | TRPV1 | Vanilloid receptor | Q8NER1 | CHEMBL4794 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 6.595E-09 | 3.590E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0032501; multicellular organismal process | GO:0050968; detection of chemical stimulus involved in sensory perception of pain | 2.459E-06 | 1.983E-03 | TRPA1, TRPV1 |
| BP | GO:0032501; multicellular organismal process | GO:0050955; thermoception | 2.459E-06 | 1.983E-03 | TRPA1, TRPV1 |
| MF | GO:0005215; transporter activity | GO:0097603; temperature-gated ion channel activity | 2.459E-06 | 1.983E-03 | TRPA1, TRPV1 |
| MF | GO:0060089; molecular transducer activity | GO:0004949; cannabinoid receptor activity | 2.459E-06 | 1.983E-03 | CNR1, CNR2 |
| BP | GO:0050896; response to stimulus | GO:0043434; response to peptide hormone | 4.378E-06 | 3.178E-03 | FABP3, PPARA, TLR2, TRPV1, TSHR |
| BP | GO:0009987; cellular process | GO:0038171; cannabinoid signaling pathway | 4.916E-06 | 3.453E-03 | CNR1, CNR2 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.228E-05 | 7.425E-03 | CYP1A2, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0051001; negative regulation of nitric-oxide synthase activity | 1.718E-05 | 8.698E-03 | CNR1, CNR2 |
| MF | GO:0005488; binding | GO:0036041; long-chain fatty acid binding | 4.489E-05 | 1.810E-02 | FABP3, PPARD |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 5.383E-05 | 1.980E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 6.359E-05 | 2.198E-02 | SMN1, SMN2 |
| MF | Unclassified; | GO:0004871; signal transducer activity | 7.374E-05 | 2.509E-02 | CNR1, CNR2, PPARA, PPARD, TLR2, TRPA1, TRPV1, TSHR |
| MF | GO:0005215; transporter activity | GO:0015278; calcium-release channel activity | 1.244E-04 | 3.564E-02 | TRPA1, TRPV1 |
| CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 1.244E-04 | 3.564E-02 | SMN1, SMN2 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 1.572E-04 | 4.173E-02 | CNR2, SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 2.425E-11 | 1.213E-09 | FABP2, FABP3, FABP4, FABP5, PPARA, PPARD |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.204E-06 | 5.510E-05 | CYP1A2, ALOX15, CYP2C19 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 9.454E-05 | 1.576E-03 | CNR2, CNR1, TRPV1, TSHR |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.145E-03 | 1.401E-02 | FABP4, TSHR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.401E-03 | 1.401E-02 | ALOX15, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.732E-03 | 1.443E-02 | CYP1A2, CYP2C19 |
| 09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.455E-03 | 2.159E-02 | TRPA1, TRPV1 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.435E-03 | 1.739E-02 | CYP1A2, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.485E-03 | 2.246E-02 | ALOX15, CYP2C19 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 4.492E-03 | 2.246E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chemotherapy-induced nausea | R11 | CNR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | CNR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | CNR2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | CNR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | CNR1; |
| C00-D49: Neoplasms | Ovarian cancer | C56 | CNR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | CNR2; CNR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Nicotine dependence | F17 | CNR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CNR2; CNR1; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | CNR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CNR1; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | CNR2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | CNR2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | CNR1; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | CNR2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | CNR1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Immune disorder | D80-D89 | CNR2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | CNR1; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | CNR1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | CNR1; |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CNR2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anorexia | F50.0-F50.1 | CNR1; |
| A00-B99: Certain infectious and parasitic diseases | Postherpetic neuralgia | B02.2, G44.847, G53.0 | CNR1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | CNR1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
